These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36618338)

  • 1. Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review.
    Taherian M; Chatterjee D; Wang H
    J Clin Transl Pathol; 2022 Sep; 2(3):83-90. PubMed ID: 36618338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
    Coukos A; Vionnet J; Obeid M; Bouchaab H; Peters S; Latifyan S; Wicky A; Michielin O; Chtioui H; Moradpour D; Fasquelle F; Sempoux C; Fraga M
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36283734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
    Singh N; Hocking AM; Buckner JH
    Immunol Rev; 2023 Sep; 318(1):81-88. PubMed ID: 37493210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review.
    Ghosh N; Chan KK; Jivanelli B; Bass AR
    J Clin Rheumatol; 2022 Mar; 28(2):e498-e505. PubMed ID: 34371516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
    Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
    Stelmachowska-Banaś M; Czajka-Oraniec I
    Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy.
    Medina P; Jeffers KD; Trinh VA; Harvey RD
    J Pharm Pract; 2020 Jun; 33(3):338-349. PubMed ID: 31694455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
    da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
    Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach.
    Tran SD; Lin J; Galvez C; Rasmussen LV; Pacheco J; Perottino GM; Rahbari KJ; Miller CD; John JD; Theros J; Vogel K; Dinh PV; Malik S; Ramzan U; Tegtmeyer K; Mohindra N; Johnson JL; Luo Y; Kho A; Sosman J; Walunas TL
    Front Immunol; 2024; 15():1331959. PubMed ID: 38558818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy.
    Rose N; Furer V; Polachek A; Elkayam O; Gertel S
    Eur J Rheumatol; 2024 Jan; 11(1):27-32. PubMed ID: 38477323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
    Yanai S; Toya Y; Sugai T; Matsumoto T
    Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy.
    Rajha E; Chaftari P; Kamal M; Maamari J; Chaftari C; Yeung SJ
    Gastroenterol Rep (Oxf); 2020 Feb; 8(1):25-30. PubMed ID: 32104583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
    Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
    Front Immunol; 2022; 13():804597. PubMed ID: 35432346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
    Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
    Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities.
    Taylor J; Gandhi A; Gray E; Zaenker P
    Front Immunol; 2022; 13():991433. PubMed ID: 36713389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.